19 May 2021 in Future Oncology
Aim: Machine learning reveals pathways to neuroendocrine tumor (NET) diagnosis. Patients & methods: Patients with NET and age-/gender-matched non-NET controls were retrospectively selected from Mar... Lay abstract We present the novel analytic approach of machine learning using real-world data to describe patient pathways to neuroendocrine tumor (NET) diagnosis. Due to the rarity and presentatio...
1 January 2021 in Journal of Medical Economics
This study describes treatment characteristics and healthcare costs prior to and following treatment change from somatostatin analog (SSA) monotherapy among a privately-insured NET patient populati...
10 June 2025 in Journal of Medical Economics
Pediatric tympanostomy tube placement (TTP) is performed primarily in operating room (OR) settings under general anesthesia. Recent studies have demonstrated TTP completed in the otolaryngologist's office with a topical anesthetic and delivery device to be safe and effective. This study estimated the financial impact to commercial and Medicaid health plans by shifting pediatric TTP from the OR to an office setting. This budget impact model estimated the financial impact of using the Hummingbirdi Tympanostomy Tube System (HTTS) for in-office pediatric tympanostomy tube placement by shifting 25% of utilization away from the OR - hospital outpatient department (HOPD) or ambulatory surgery center (ASC) - in a commercially- and Medicaid-insured population. The annual TTP estimate in a one-million-member health plan was 2,872 for a commercial plan and 4,534 for a Medicaid plan. Cost inputs for HOPD and ASC procedures were $5,743 and $3,609 (Commercial) and $2,199 and $1,663 (Medicaid), respectively. Cost inputs for in-office procedures utilizing HTTS were $2,000 (Commercial) and $1,600 (Medicaid). All surgical cost estimates assumed a bilateral (two ear) procedure. A 25% shift led to cost savings of $1,991,790 (14.5%) for commercial plans and $365,562 (4.2%) for Medicaid plans; translating into $0.17 per member per month (PMPM) and $58 per treated member per month (PTMPM) savings in a commercial plan and $0.03 PMPM and $7 PTMPM in Medicaid. Per patient cost of TTP decreased by $3,743/65.2% (HOPD) or $1,609/44.6% (ASC) for Commercial and $519/24.5% (HOPD) and $63/3.8% (ASC) for Medicaid. Costs in HOPD and ASC setting were based on averages in the MarketScan administrative claims databases which are limited by contributor, data coding, and entry errors. In-office TTP utilizing HTTS substantially reduces cost for U.S. commercial and Medicaid health insurers, offering a significant opportunity to deliver value-based care.
5 May 2026 in Journal of Medical Economics
This retrospective, longitudinal, observational study evaluated the incidence of opioid use disorder (OUD) among patients newly initiating opioids to manage acute and chronic pain in the United States. Additionally, healthcare resource utilization (HCRU) and associated costs were analyzed. Adult patients newly treated with prescription opioids were identified within the MarketScan administrative claims databases (2016-2018). Patients were classified as experiencing acute or chronic pain based on total prescription pain medication use within one year of the initial opioid prescription. Subgroups of patients with or without OUD were identified using diagnosis codes. The 1-, 2-, and 3-year incidence rates of OUD were 0.21%, 0.32%, and 0.43%, respectively, among acute pain patients and 1.11%, 1.52%, and 1.92% among chronic pain patients. Unadjusted all-cause HCRU were substantially higher among patients with OUD compared to those without OUD over the 12-month period following OUD diagnosis. The associated unadjusted total all-cause healthcare costs were 3.1-times and 2.0-times higher for those with OUD compared to those without OUD in the acute and chronic pain cohorts, respectively. The total all-cause healthcare costs for patients with OUD remained significantly higher, even after adjusting for baseline characteristics. When extrapolated nationally, estimated costs for patients managing acute or chronic pain and newly diagnosed with OUD were $3.3 billion (B) and $5.9B, respectively, totaling $9.2B. Pain medication use was identified using claims for filled prescriptions; patients' actual medication usage and use of over-the-counter medications cannot be ascertained. OUD diagnosis was based on specific ICD-10-CM diagnosis codes, potentially underestimating the true incidence and economic impact. Newly diagnosed OUD following prescription opioid use for managing acute and chronic pain imposes a substantial economic burden within the first year following OUD diagnosis. Increased use of effective non-opioid analgesics may help reduce the incidence and economic burden of OUD.